2003年7月,FDA批准惠氏公司的0.3和0.45mg的倍美力(结合雌激素片剂,conjugated estrogenstablets,Premarin) 用于绝经妇女的骨质疏松症预防。这一许可基于一项前瞻性临床研究,该研究显示,低剂量本品与目前用于预防有绝经期症状的绝经妇女的骨质丢失的标准剂量疗效相当。同期,FD In July 2003, the FDA approved Wyeth’s 0.3 and 0.45 mg of betamethasone (conjugated estrogenstablets, Premarin) for the prevention of osteoporosis in postmenopausal women. This approval is based on a prospective clinical study showing that low doses of this product have comparable efficacy to standard doses of bone loss currently used in menopausal women with menopausal symptoms. Over the same period, FD